Abstract
Purpose :
To investigate the safety and efficacy of a new micro-controlled radiofrequency device for treatment of conjunctivochalsis (Cch).
Methods :
Data of 127 patients (230 eyes) who underwent ophthalmic radiofrequency treatment for Cch from January 2020 to June 2023 were analyzed retrospectively. Cch coagulation was performed with a radiofrequency electrode tip (OcuRF®, Ilooda, Korea) and a high-frequency radio-wave electric unit (0.6~0.8 watts, 2 MHz, Acutron™, Ilooda, Korea). Pre- and post-operative Cch grading, silt-lamp photography, tear film beak-up time (TBUT), and bulbar conjunctival hyperemia using Keratograph 5M (Oculus®, Wetzlar, Germany) were evaluated. Cch grade 0 or 1 after surgery was regarded as 'success'. Complications, recurrence, and additional treatment rate were analyzed.
Results :
In 225 (97.8%) eyes, the radiofrequency treatment led to marked improvement of Cch, with 224 (97.4%) eyes achieving grade 0 or 1 at 2-months postoperatively. Eight eyes (3.5%) received additional treatment. TBUT improved from 3.17 ± 0.82 seconds to 5.28 ± 1.10 seconds after surgery (P<0.001). Total bulbar conjunctival hyperemia value showed an improvement from 1.7 ± 0.6 to 1.4 ± 0.6 postoperatively (P<0.05). No serious complications were observed.
Conclusions :
The novel ophthalmic radiofrequency device led to marked improvement of Cch with no serious adverse events during the entire follow-up period. Our results suggest that the radiofrequency device presents a safe and efficacious treatment option for Cch.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.